FDA abortion – The FDA confirmed its safety review of mifepristone will extend into early 2027, drawing immediate criticism from anti-abortion groups.
The safety review of the nation’s primary abortion pill, mifepristone, will remain active well into next year, the Food and Drug Administration confirmed in a court-ordered filing late Wednesday.
This timeline marks the first substantive insight into the reevaluation ordered by Health Secretary Robert F. Kennedy Jr. While the FDA has maintained the pill’s safety since its initial 2000 approval—repeatedly reaffirming its effectiveness and even loosening dispensing requirements—the current administration faces mounting pressure from anti-abortion groups and congressional allies to tighten access.
Under the newly outlined schedule, the agency expects to conclude a safety study by mid-December. However. the final report detailing these findings is not slated for completion until “no later than March 2027.” Only after that report is finalized will the FDA determine whether to implement new restrictions or modify how the drug is used.
Gavin Oxley of Americans United for Life characterized the extended timeline as a failure of “true leadership” within the Trump administration. “The administration continues to find itself on the wrong side of women’s health. clearly uninterested in mitigating the ongoing harms caused by the abortion pill. ” Oxley said.
The regulatory delay highlights the growing friction between long-standing federal drug approval standards and intensifying state-level legal challenges. Currently. a federal appeals court in New Orleans is overseeing a lawsuit brought by the state of Louisiana. which argues that the mail-delivery of mifepristone undermines local abortion bans. This case is one of several similar legal efforts currently moving through the court system.
The stakes remain high for the medical landscape, as the two-drug regimen of mifepristone and misoprostol remains the most common method of abortion in the United States.
FDA mifepristone abortion pill Robert F. Kennedy Jr abortion access Louisiana lawsuit reproductive health